Akero Therapeutics, Inc.

NasdaqGS:AKRO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 4.32 B

Share Price

USD 54.20

Avg Daily Volume

1,443,244

Change (1 day)

-1.27%

Change (1 year)

148.85%

Change (YTD)

94.82%

Akero Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending March 31, 2025

Akero Therapeutics, Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending March 31, 2025. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Akero Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending March 31, 2022 was -54.03%.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Return on Assets (ROA)	Revenue Per Share	Free Cash Flow Per Share	Dividend Per Share

NasdaqGS: AKRO

Akero Therapeutics, Inc.

CEO	Dr. Andrew Cheng M.D., Ph.D.
IPO Date	June 20, 2019
Location	United States
Headquarters	601 Gateway Boulevard
Employees	69
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.